News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

MediStem, Inc. (Formerly known as Medistem Laboratories, Inc.) Industry/Academia Collaboration Leads to Nanotechnology Based


4/17/2012 11:37:39 AM

SAN DIEGO, CA--(Marketwire - April 13, 2012) - Medistem Inc. (PINKSHEETS: MEDS) announced today it has co-authored a peer-reviewed publication disclosing a new approach to stimulating the immune system to kill tumor cells using a novel nanotechnology-based approach.

In the publication (PLGA nanoparticle-mediated delivery of tumor antigenic peptides elicits effective immune responses. International Journal of Nanomedicine, 7: 1475, 2012) Medistem and a team of collaborators demonstrated that nanoparticles could be used to deliver molecules found on tumors to specific cells of the immune system called "dendritic cells." These nanoparticle-loaded dendritic cells were then able to stimulate other cells of the immune system to directly kill tumors in the test tube and also in mice bearing prostate cancer.

"Cellular therapy is a clinical reality, for example, the company Dendreon developed the first therapeutic FDA-approved cancer vaccine Sipuleucel-T (Provenge) that is currently being used for treatment of patients with hormone-resistant prostate cancer. The data we published today provides ways of optimizing treatments such as Provenge," said Dr. Vladimir Bogin, President and Chairman of Medistem. "By using nanotechnology to specifically educate dendritic cells to activate the immune system in patients, it may be possible to develop more effective ways of treating cancer by leveraging the body's own resources."

The senior author of the publication, Dr. Boris Minev, is faculty at the Moores Cancer Center, and at the Division of Neurosurgery of the University of California, as well as Director of Immunotherapy and Translational Oncology at Genelux Corporation. Additional collaborators included the Laboratory of Biomaterials and Nanotechnology, University of California Riverside, the Division of Neurosurgery, of University of California Los Angeles, and the Chemistry Department at San Diego State University.

"For more than 4 years, I have thoroughly enjoyed collaborating with the Medistem Team, in areas including treatment of multiple sclerosis, cancer immunotherapy, rheumatoid arthritis, and now nanotechnology. The common theme of our collaboration is leveraging the body's own resources as a therapeutic," said Dr. Boris Minev. "In addition to the recently announced clinical trials for Medistem's Endometrial Regenerative Cell (ERC) universal donor stem cell, I am looking forward to clinical translation of other products of our collaboration."

To date Medistem and Dr. Minev have published 12 peer-reviewed papers together. Dr. Minev was co-author on Medistem's original paper describing human use of the ERC in patients with multiple sclerosis (click here for link http://www.translational-medicine.com/content/pdf/1479-5876-7-15.pdf), as well as several other basic research and clinical publication. Medistem has filed US provisional patent # 61/592,636 covering naturally-derived nanoparticles generated by ERC.

Cautionary Statement

This press release does not constitute an offer to sell or a solicitation of an offer to buy any of our securities. This press release may contain certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking information. Factors which may cause actual results to differ from our forward-looking statements are discussed in our Form 10-K for the year ended December 31, 2007 as filed with the Securities and Exchange Commission.


Medistem Contact:
Lisa Brock
Director of Investor Relations
Lisa.brock@medisteminc.com
503.381.4618

Medistem Inc.
9255 Towne Centre Drive
Suite 450
San Diego, CA 92122
www.medisteminc.com
Twitter: @medistem

Digg this    Bookmark with del.icio.us    Add to Newsvine

Technorati:


Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES